Heterozygous mutations in natriuretic peptide receptor-B (NPR2) are associated with short stature

Robert C. Olney, Hülya Bükülmez, Cynthia F. Bartels, Timothy C.R. Prickett, Eric A. Espiner, Lincoln R Potter, Matthew L. Warman

Research output: Contribution to journalArticle

105 Citations (Scopus)

Abstract

Context: C-type natriuretic peptide (CNP) is an important regulator of skeletal growth. Loss-of-function mutations affecting the CNP receptor natriuretic peptide receptor-B (gene NPR2) cause the autosomal recessive skeletal dysplasia, acromesomelic dysplasia, Maroteaux type (AMDM). The phenotype of heterozygous carriers of NPR2 mutations is less clear. Objective: The objective of the study was to determine the phenotypic features of heterozygous carriers of NPR2 mutations. Design and Setting: This was a case-control study from the general community. Subjects: Thirty-nine members of a family in which one member has AMDM were studied. Intervention: This was an observational study. Main Outcome Measure: The primary measure was stature, with the hypothesis that carriers have reduced stature compared with noncarriers. Results: Sixteen family members were NPR2 mutation carriers. Height z-scores of these carriers were -1.8 ± 1.1 (mean ± SD), which was significantly less than the 23 noncarrier family members (-0.4 ± 0.8, P < 0.0005) and the general population (P < 0.0005). However, there was no difference in body proportion between carriers and noncarriers. The proband with AMDM had low IGF-I levels and evidence of GH resistance, as well as very high plasma levels of CNP and its amino-terminal propeptide. Levels of these peptides were normal in the heterozygous carriers. Conclusions: We have shown that heterozygous mutations in NPR2 are associated with short stature. Assuming one in 700 people unknowingly carry an NPR2 mutation, our data suggest that approximately one in 30 individuals with idiopathic short stature are carriers of NPR2 mutations.

Original languageEnglish (US)
Pages (from-to)1229-1232
Number of pages4
JournalJournal of Clinical Endocrinology and Metabolism
Volume91
Issue number4
DOIs
StatePublished - Apr 1 2006

Fingerprint

C-Type Natriuretic Peptide
Mutation
Insulin-Like Growth Factor I
Genes
Plasmas
Peptides
atrial natriuretic factor receptor B
Observational Studies
Case-Control Studies
Outcome Assessment (Health Care)
Phenotype
Growth

Cite this

Heterozygous mutations in natriuretic peptide receptor-B (NPR2) are associated with short stature. / Olney, Robert C.; Bükülmez, Hülya; Bartels, Cynthia F.; Prickett, Timothy C.R.; Espiner, Eric A.; Potter, Lincoln R; Warman, Matthew L.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 91, No. 4, 01.04.2006, p. 1229-1232.

Research output: Contribution to journalArticle

Olney, Robert C. ; Bükülmez, Hülya ; Bartels, Cynthia F. ; Prickett, Timothy C.R. ; Espiner, Eric A. ; Potter, Lincoln R ; Warman, Matthew L. / Heterozygous mutations in natriuretic peptide receptor-B (NPR2) are associated with short stature. In: Journal of Clinical Endocrinology and Metabolism. 2006 ; Vol. 91, No. 4. pp. 1229-1232.
@article{632010b469aa4c1d96946646a988d111,
title = "Heterozygous mutations in natriuretic peptide receptor-B (NPR2) are associated with short stature",
abstract = "Context: C-type natriuretic peptide (CNP) is an important regulator of skeletal growth. Loss-of-function mutations affecting the CNP receptor natriuretic peptide receptor-B (gene NPR2) cause the autosomal recessive skeletal dysplasia, acromesomelic dysplasia, Maroteaux type (AMDM). The phenotype of heterozygous carriers of NPR2 mutations is less clear. Objective: The objective of the study was to determine the phenotypic features of heterozygous carriers of NPR2 mutations. Design and Setting: This was a case-control study from the general community. Subjects: Thirty-nine members of a family in which one member has AMDM were studied. Intervention: This was an observational study. Main Outcome Measure: The primary measure was stature, with the hypothesis that carriers have reduced stature compared with noncarriers. Results: Sixteen family members were NPR2 mutation carriers. Height z-scores of these carriers were -1.8 ± 1.1 (mean ± SD), which was significantly less than the 23 noncarrier family members (-0.4 ± 0.8, P < 0.0005) and the general population (P < 0.0005). However, there was no difference in body proportion between carriers and noncarriers. The proband with AMDM had low IGF-I levels and evidence of GH resistance, as well as very high plasma levels of CNP and its amino-terminal propeptide. Levels of these peptides were normal in the heterozygous carriers. Conclusions: We have shown that heterozygous mutations in NPR2 are associated with short stature. Assuming one in 700 people unknowingly carry an NPR2 mutation, our data suggest that approximately one in 30 individuals with idiopathic short stature are carriers of NPR2 mutations.",
author = "Olney, {Robert C.} and H{\"u}lya B{\"u}k{\"u}lmez and Bartels, {Cynthia F.} and Prickett, {Timothy C.R.} and Espiner, {Eric A.} and Potter, {Lincoln R} and Warman, {Matthew L.}",
year = "2006",
month = "4",
day = "1",
doi = "10.1210/jc.2005-1949",
language = "English (US)",
volume = "91",
pages = "1229--1232",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "4",

}

TY - JOUR

T1 - Heterozygous mutations in natriuretic peptide receptor-B (NPR2) are associated with short stature

AU - Olney, Robert C.

AU - Bükülmez, Hülya

AU - Bartels, Cynthia F.

AU - Prickett, Timothy C.R.

AU - Espiner, Eric A.

AU - Potter, Lincoln R

AU - Warman, Matthew L.

PY - 2006/4/1

Y1 - 2006/4/1

N2 - Context: C-type natriuretic peptide (CNP) is an important regulator of skeletal growth. Loss-of-function mutations affecting the CNP receptor natriuretic peptide receptor-B (gene NPR2) cause the autosomal recessive skeletal dysplasia, acromesomelic dysplasia, Maroteaux type (AMDM). The phenotype of heterozygous carriers of NPR2 mutations is less clear. Objective: The objective of the study was to determine the phenotypic features of heterozygous carriers of NPR2 mutations. Design and Setting: This was a case-control study from the general community. Subjects: Thirty-nine members of a family in which one member has AMDM were studied. Intervention: This was an observational study. Main Outcome Measure: The primary measure was stature, with the hypothesis that carriers have reduced stature compared with noncarriers. Results: Sixteen family members were NPR2 mutation carriers. Height z-scores of these carriers were -1.8 ± 1.1 (mean ± SD), which was significantly less than the 23 noncarrier family members (-0.4 ± 0.8, P < 0.0005) and the general population (P < 0.0005). However, there was no difference in body proportion between carriers and noncarriers. The proband with AMDM had low IGF-I levels and evidence of GH resistance, as well as very high plasma levels of CNP and its amino-terminal propeptide. Levels of these peptides were normal in the heterozygous carriers. Conclusions: We have shown that heterozygous mutations in NPR2 are associated with short stature. Assuming one in 700 people unknowingly carry an NPR2 mutation, our data suggest that approximately one in 30 individuals with idiopathic short stature are carriers of NPR2 mutations.

AB - Context: C-type natriuretic peptide (CNP) is an important regulator of skeletal growth. Loss-of-function mutations affecting the CNP receptor natriuretic peptide receptor-B (gene NPR2) cause the autosomal recessive skeletal dysplasia, acromesomelic dysplasia, Maroteaux type (AMDM). The phenotype of heterozygous carriers of NPR2 mutations is less clear. Objective: The objective of the study was to determine the phenotypic features of heterozygous carriers of NPR2 mutations. Design and Setting: This was a case-control study from the general community. Subjects: Thirty-nine members of a family in which one member has AMDM were studied. Intervention: This was an observational study. Main Outcome Measure: The primary measure was stature, with the hypothesis that carriers have reduced stature compared with noncarriers. Results: Sixteen family members were NPR2 mutation carriers. Height z-scores of these carriers were -1.8 ± 1.1 (mean ± SD), which was significantly less than the 23 noncarrier family members (-0.4 ± 0.8, P < 0.0005) and the general population (P < 0.0005). However, there was no difference in body proportion between carriers and noncarriers. The proband with AMDM had low IGF-I levels and evidence of GH resistance, as well as very high plasma levels of CNP and its amino-terminal propeptide. Levels of these peptides were normal in the heterozygous carriers. Conclusions: We have shown that heterozygous mutations in NPR2 are associated with short stature. Assuming one in 700 people unknowingly carry an NPR2 mutation, our data suggest that approximately one in 30 individuals with idiopathic short stature are carriers of NPR2 mutations.

UR - http://www.scopus.com/inward/record.url?scp=33646035837&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646035837&partnerID=8YFLogxK

U2 - 10.1210/jc.2005-1949

DO - 10.1210/jc.2005-1949

M3 - Article

C2 - 16384845

AN - SCOPUS:33646035837

VL - 91

SP - 1229

EP - 1232

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 4

ER -